Glaxo Pays $175 Million To Settle Antitrust Suit Over Relafen Patent
GlaxoSmithKline has agreed to pay $175 million to settle a lawsuit alleging that the company had violated U.S. antitrust law by blocking generic versions of its Relafen arthritis medicine....To view the full article, register now.
Already a subscriber? Click here to view full article